Chimerix
Chimerix is a biopharmaceutical company focused on developing innovative medicines, particularly in the field of neuro-oncology, with a mission to improve patient outcomes through scientific research and clinical development. It is now part of Jazz Pharmaceuticals, aiming to advance its scientific and therapeutic goals.
Industries
Nr. of Employees
medium (51-250)
Chimerix
2505 Meridian Parkway, Suite 100, Durham, NC 27713
Patents
Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
US-11111264-B2
View Details
Morphic forms of 4-amino-7-(3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-2-methyl-7H-pyrrolo[2,3-d]pyrimidine-5-carboxamide and uses thereof
US-11111264-B2
View DetailsProducts
Imipridone-class investigational oncology small molecules
Investigational small-molecule oncology agents of the imipridone class evaluated in preclinical models and clinical studies for high-grade gliomas and H3 K27M–mutant diffuse midline glioma.
Nucleoside analog antiviral candidate
A nucleoside-analog antiviral candidate demonstrated to inhibit SARS‑CoV‑2 in human airway epithelial cultures and to provide prophylactic and therapeutic efficacy in mouse respiratory disease models.
Imipridone-class investigational oncology small molecules
Investigational small-molecule oncology agents of the imipridone class evaluated in preclinical models and clinical studies for high-grade gliomas and H3 K27M–mutant diffuse midline glioma.
Nucleoside analog antiviral candidate
A nucleoside-analog antiviral candidate demonstrated to inhibit SARS‑CoV‑2 in human airway epithelial cultures and to provide prophylactic and therapeutic efficacy in mouse respiratory disease models.
Services
Coordination and administration of expanded access/compassionate use requests and program logistics for investigational therapies.
Medical-scientific engagement with healthcare professionals and support for investigator interactions and trial-related inquiries.
Preparation and dissemination of abstracts, posters and presentations for scientific meetings and peer-reviewed journals.
Mechanisms for identifying, documenting and reporting adverse events from social channels and other sources to drug safety teams and regulators.
Coordination and administration of expanded access/compassionate use requests and program logistics for investigational therapies.
Medical-scientific engagement with healthcare professionals and support for investigator interactions and trial-related inquiries.
Preparation and dissemination of abstracts, posters and presentations for scientific meetings and peer-reviewed journals.
Mechanisms for identifying, documenting and reporting adverse events from social channels and other sources to drug safety teams and regulators.
Expertise Areas
- Clinical trial management
- Neuro-oncology research and development
- Preclinical antiviral development
- Biomarker discovery and validation
Key Technologies
- Cell-culture antiviral assays
- Mouse efficacy models
- Biomarker assay development
- Small-molecule pharmacology
News & Updates
Chimerix sponsored the SNO Annual Meeting held in Vancouver, Canada from November 16 – 19, 2023, featuring discussions on H3 K27M-mutant diffuse glioma and related clinical trials.
Chimerix participated in the 2024 SNO Conference in Houston, TX, with presentations on recurrent H3 K27M-mutant diffuse midline glioma and preclinical studies of ONC206.
Chimerix published several scientific articles on neuro-oncology topics, including disease definition, treatment landscape, and therapeutic potential in gliomas.
A scientific publication discussing the anti-cancer properties of imipridones, including ONC201 and ONC206.
Chimerix sponsored the SNO Annual Meeting held in Vancouver, Canada from November 16 – 19, 2023, featuring discussions on H3 K27M-mutant diffuse glioma and related clinical trials.
Chimerix participated in the 2024 SNO Conference in Houston, TX, with presentations on recurrent H3 K27M-mutant diffuse midline glioma and preclinical studies of ONC206.
Chimerix published several scientific articles on neuro-oncology topics, including disease definition, treatment landscape, and therapeutic potential in gliomas.
A scientific publication discussing the anti-cancer properties of imipridones, including ONC201 and ONC206.